Modulation of melanocortin signaling ameliorates uremic cachexia  by Cheung, Wai W. et al.
see commentary on page 143
Modulation of melanocortin signaling ameliorates
uremic cachexia
Wai W. Cheung1, Sanna Rosengren2, David L. Boyle2 and Robert H. Mak1
1Division of Pediatric Nephrology, Department of Pediatrics, University of California at San Diego, La Jolla, California, USA and
2Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California at
San Diego School of Medicine, La Jolla, California, USA
Insulin-like growth factor (IGF)-I increases muscle mass while
myostatin inhibits its development. Muscle wasting is
common in patients with uremic cachexia and may be due to
imbalance of this regulation. We had proposed a central
mechanism involving leptin and melanocortin signaling in
the pathogenesis of uremic cachexia since agouti-related
peptide (AgRP), a melanocortin-4 receptor antagonist,
reduced uremic cachexia. Here we found that injection of
AgRP into the cerebral ventricles resulted in a gain of body
mass and improved metabolic rate regulation in a mouse
model of uremic cachexia. These salutary effects occurred
independent of increased protein and calorie intake.
Myostatin mRNA and protein concentrations were increased
while those of IGF-I were decreased in the skeletal muscle of
uremic mice. AgRP treatment partially corrected these
uremia-induced changes. Suppressor of cytokine signaling-2
gene expression (SOCS2) was significantly increased in
uremic animals and AgRP reduced this expression. We
suggest that AgRP improves uremic cachexia and muscle
wasting by a peripheral mechanism involving the balance
between myostatin and IGF-I.
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The cachexia syndrome in patients with chronic kidney
disease (CKD) consists of decreased protein stores, anorexia,
and increased energy expenditure. It is to be distinguished
from malnutrition, which is defined as the consequence of
insufficient food or an improper diet. Responses in
malnutrition are adaptive, whereas those in cachexia are
maladaptive. In malnutrition, such as in simple starvation,
fats are preferentially lost and lean body mass (LBM) is
preserved. In cachexia, muscle mass is wasted and fats are
relatively underutilized. Hunger characterizes malnutrition,
which is an adaptive response. On the other hand, anorexia is
prevalent in patients with end-stage renal disease, occurring
in one-third of patients on dialysis.
The pathogenesis of uremic muscle wasting is poorly
understood.1–4 A considerable amount of progress has been
made in our understanding of the signaling pathways that
mediate skeletal muscle mass regulation. Recent studies have
highlighted the important roles of insulin-like growth factor
(IGF)-I and myostatin in the pathogenesis of muscle
wasting.5,6 IGF-I and myostatin play stimulatory and
inhibitory roles, respectively, in the regulation of muscle
mass. Muscle wasting is common in patients with uremic
cachexia and may be due to the imbalance of this regulation.7
Suppressor of cytokine signaling (SOCS)-2 is a negative
regulator of growth hormone (GH) action and may be
involved in this dysregulation. Recently, we proposed that
there is a central mechanism involving leptin and melano-
cortin signaling in the pathogenesis of uremic cachexia.8 We
showed that agouti-related peptide (AgRP), a melanocortin-4
receptor (MC4-R) reverse agonist, ameliorated uremic
cachexia.9 However, the peripheral mechanism of this
potential therapeutic strategy is not known. We investigated
myostatin and IGF-I balance as well as the potential
regulatory role of SOCS-2 in a mouse model of uremic
cachexia.
RESULTS
Cachexia in nephrectomized mice
Male c57BL/6J mice were used for this study. Nephrecto-
mized (N) mice, fed on 17% protein diet, were uremic but
not acidotic. N mice had higher levels of blood urea nitrogen
and creatinine (65.9±2.3 and 0.6±0.1 mg per 100 ml,
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respectively; n¼ 8) than sham-operated (S) mice (30.7±1.2
and 0.2±0.0 mg per 100 ml, respectively; n¼ 8, Po0.001;
Table 1). Blood bicarbonate levels were not different in N
mice (26.4±1.4 mmol l1) and S mice (26.7±1.1 mmol l1;
Table 1).
N mice were fed ad libitum (57.2±2.1 g), whereas S
mice were pair-fed (57.2±2.1 g; Figure 1a) for the study
period of 14 days. N mice were cachectic. N mice gained less
weight (gain of 0.5±0.1 g) compared with pair-fed S mice
(gain of 1.8±0.2 g; Po0.001; Figure 1b). N mice continued
to lose LBM and fat mass (FM) (loss of 1.6±0.3 and
3.2±0.6%, respectively), whereas S mice gained LBM and
FM (gain of 4.2±0.4 and 8.6±2.3%, respectively; Po0.001;
Figure 2a and b).
Basal metabolic rate was increased in N mice
(4264±101 ml kg1 h1) compared with that in S mice
(3806±72 ml kg1 h1; Po0.001; Figure 3a). Conversely,
efficiency of food consumption (calculated as the cumulative
weight gain (in g) divided by total food consumption (in g))
was decreased in N mice (0.012±0.003) compared with that
in pair-fed S mice (0.028±0.006; Po0.001; Figure 3b).
AgRP administration attenuates uremic-associated cachexia
Uremic cachexia in subtotal N mice was attenuated
by intracranial administration of AgRP. AgRP-treated N
(N/AgRP) mice were still uremic but not acidotic. N/AgRP
mice had higher blood urea nitrogen and creatinine levels
(63.2±1.6 and 0.6±0.0 mg per 100 ml, respectively; n¼ 8)
than S mice (Po0.001; Table 1). Blood bicarbonate levels in
N/AgRP mice (26.3±0.7 mmol l1) were comparable to
those in S mice (Table 1).
N/AgRP mice resisted uremic-associated cachexia. Our
previous results indicated that administration of AgRP
significantly increased the daily food intake of uremic mice.9
To ensure that the observed effects on body mass regulation
were not due to the effects of different nutritional intake,
N/AgRP mice were pair-fed (57.2±2.1 g; Figure 1a) to N
mice. N/AgRP mice gained more weight (gain of 1.2±0.2 g)
than N mice (Po0.001; Figure 1b). N/AgRP mice gained
LBM and FM (gain of 2.2±0.5 and 3.2±0.4%, respectively),
whereas N mice continued to lose LBM and FM (Po0.001;
Table 1 | Serum chemistry of experimental mice
S N N/AgRP
(n=8) (n=8) (n=8)
Initial body weight (g) 19.4±0.3 19.4±0.1 19.5±0.4
Serum chemistry
BUN (mg per 100 ml) 30.7±1.2 65.9±2.3# 63.2±1.6#
Creatinine (mg per 100 ml) 0.2±0.0 0.6±0.1# 0.6±0.0#
Bicarbonate (mmol l1) 26.7±1.1 26.4±1.4 26.3±0.7
AgRP, agouti-related peptide; BUN, blood urea nitrogen; N, nephrectomized; S,
sham-operated.
Animals were killed at the end of 14 days. Three groups of mice were compared: S
(sham-operated) and N (nephrectomized) versus N/AgRP (nephrectomized treated
with AgRP). Data are expressed as mean±s.e.m. #Po0.001.
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Figure 1 | Cumulative food consumption and weight gain of
experimental mice. (a) Cumulative food consumption and
(b) cumulative weight gain during a 14-day study. N mice were
fed ad libitum, whereas S and N/AgRP mice were pair-fed with N
mice. Data are expressed as mean±s.e.m. *Po0.001.
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Figure 2 | Change in LBM and FM of experimental mice.
Experimental mice were scanned by DEXA to determine the
change in (a) LBM and (b) FM. Animals were scanned 1 day
before the starting of the experiment, followed 14 days
later by a second DEXA scan. Final results as percent change
from baseline are expressed as mean±s.e.m. *Po0.001.
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Figure 2a and b). Blockade of the MC4-R is associated with a
decrease in basal oxygen consumption. Comparable to S
mice, basal metabolic rate was decreased in N/AgRP mice
(3916±107 ml kg1 h1) than N mice (Po0.001; Figure 3a).
In addition, N/AgRP mice had higher efficiency of
food consumption (0.019±0.006) than N mice (Po0.001;
Figure 3b).
Effects of AgRP administration on IGF-I, myostatin, SOCS-2,
and SOCS-3 gene expression in uremic-associated cachexia
IGF-I mRNA expression was significantly decreased in
gastrocnemius muscles and white adipose tissue (WAT) of
N mice (0.37±0.02 and 0.52±0.04, respectively) when
compared with pair-fed control S mice (1.00±0.02 and
1.00±0.03; Po0.001; Figures 4a and 5a). Conversely,
myostatin mRNA expression was higher in gastrocnemius
muscle and WAT of N mice (8.21±0.14 and 2.76±0.31,
respectively) than that of S mice (1.00±0.03 and 1.00±0.07;
Po0.001; Figures 4b and 5b). In addition, SOCS-2 mRNA
content in gastrocnemius muscle was higher in N mice
(4.32±0.15) than that in S mice (1.00±0.02; Po0.001;
Figure 4c), whereas there was no difference in SOCS-2 mRNA
levels in WAT of the N mice compared with those of S
controls (0.91±0.05 and 1.00±0.12; NS; Figure 5c). Similar
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Figure 3 | Basal metabolic rate and efficiency of food
consumption of experimental mice. (a) Basal metabolic rate and
(b) efficiency of food consumption were measured in
experimental animals at the end of the study. Basal metabolic rate
(ml kg1 h1) is calculated as the average of the lowest three
readings obtained during the recording period. Efficiency of food
consumption is calculated as the cumulative weight gain (in g)
divided by total food consumption (in g). Results are expressed as
mean±s.e.m. *Po0.001.
S
0
6 1
0.5
0
4
2
0
IG
F-
I m
RN
A 
lev
e
ls
 
(ar
bit
ary
 u
ni
ts
)
SO
CS
-3
 m
RN
A 
lev
e
ls
 
(ar
bit
ary
 u
ni
ts
)
SO
CS
-2
 m
RN
A 
lev
e
ls
 
(ar
bit
ary
 u
ni
ts
)
M
yo
st
at
in
 m
R
N
A 
le
ve
ls
 
(ar
bit
ary
 u
ni
ts
)
0.5
1 8
6
4
2
0
N N/AgRP
∗
∗
∗
∗
#
(n=8) (n=8) (n=8)
S N N/AgRP
(n=8) (n=8) (n=8)
S N N/AgRP
(n=8) (n=8) (n=8)
S N N/AgRP
(n=8) (n=8) (n=8)
Figure 4 | Gene expression in gastrocnemius muscle. The
comparative 2DDCt method was used to determine the relative
quantification of (a) IGF-I, (b) myostatin, (c) SOCS-2, and (d) SOCS-3
mRNA content. To normalize each sample for RNA content, the
control gene GAPDH was used. Relative quantification of the
target gene was related to the PCR signal of the specific transcript
of pair-fed S control mice. Final results were expressed in arbitrary
units, with 1 unit being the mean mRNA level determined in the
pair-fed S control mice. Data are expressed as mean±s.e.m.
*Po0.001; #Po0.003.
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Figure 5 | Gene expression in WAT. The relative quantification of
(a) IGF-I, (b) myostatin, (c) SOCS-2, and (d) SOCS-3 mRNA was
analyzed and expressed as in Figure 4. *Po0.001.
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results were obtained with cDNA of SOCS-3, as there was no
difference in SOCS-3 mRNA levels in gastrocnemius muscle
and WAT of N mice (0.95±0.07 and 1.13±0.06) compared
with those of S controls (1.00±0.07 and 1.00±0.08; NS;
Figures 4d and 5d).
We investigated the peripheral mechanism of AgRP
administration. Intracranial administration of AgRP cor-
rected IGF-I mRNA abnormalities in gastrocnemius muscle
and WAT of N/AgRP mice (0.92±0.11 and 0.89±0.12;
Figures 4a and 5a). Results also demonstrated that AgRP
significantly decreased gastrocnemius muscle and WAT
myostatin mRNA expression in N/AgRP mice (2.45±0.22
and 2.29±0.21), although the latter was still higher than that
in the S mice (Po0.001; Figures 4b and 5b). Moreover,
muscle SOCS-2 mRNA content was significantly reduced in
N/AgRP mice (1.63±0.21) compared with that of N mice,
although still higher than that of S mice (Po0.003; Figure
4c), whereas there was no difference in SOCS-2 mRNA levels
in WAT of N/AgRP mice (0.97±0.04; NS; Figure 5c)
compared with those of N or S mice. There was no difference
in SOCS-3 mRNA levels in gastrocnemius muscle and WAT
of N/AgRP mice (0.98±0.04 and 1.08±0.05; NS; Figures 4d
and 5d) compared with those of N or S mice.
IGF-I and myostatin content in gastrocnemius muscle was
determined by colorimetric ELISA (enzyme-linked immuno-
sorbent assay) kits to quantitate protein concentrations. In
four mice from each study group, we determined IGF-I and
myostatin protein concentration in extracted muscle tissue.
IGF-I protein concentration in muscle was significantly lower
in N mice (60.2±4.9 pg mg1) than that in S mice
(247.8±100.1 pg mg1; Po0.03; Figure 6a). The amount of
IGF-I protein in muscle was not different in N/AgRP mice
(134.3±18.4 pg mg1; NS; Figure 6a) compared with S mice.
Conversely, myostatin protein concentration in muscle was
significantly elevated in N mice (2.9±0.2 pg mg1) compared
with S mice (1.6±0.1 pg mg1; Po0.03; Figure 6b). Admin-
istration of AgRP decreased myostatin protein concentration
in uremic mice. Muscle myostatin concentration in N/AgRP
mice (2.3±0.1 pg mg1) was lower than that in N mice,
although still higher than that in S mice (Po0.03; Figure 6b).
DISCUSSION
We have recently demonstrated that elevated circulating levels
of cytokines such as leptin may be an important cause of
uremia-associated cachexia via signaling through the hy-
pothalamic melanocortin system.9,10 We previously showed
that administration of AgRP to mice with CKD resulted in an
increase in food intake, normalization of basal metabolic rate,
and gains in total body weight as well as LBM.9,10 These
results suggest that CKD causes a partial defect in the ability
of AgRP to block MC4-Rs in the hypothalamus. However, the
nutritional effect of increased intake of protein and calories
following AgRP administration has not been ruled out as an
important mechanism for ameliorating uremic cachexia.
In this study, we set out to test the hypothesis that AgRP
has salutary effects on uremic cachexia beyond the
nutritional effects of appetite stimulation and additional
protein and caloric intake. The first group of uremic mice
was fed ad libitum. The second group of uremic mice
receiving AgRP and sham control mice were pair-fed to the
first group of uremic mice, so that the observed effects on body
mass regulation was not due to the effects of different
nutritional intake. All three groups of mice had intracranial
cannulation and the uremic and sham group received solvent
injection, whereas the uremic AgRP group received AgRP to
avoid additional unintended effects of the surgical procedures.
We showed that AgRP significantly ameliorated body mass and
metabolic rate regulation in our mouse model of uremic
cachexia and that these salutary effects occurred independently
of increased nutritional intake of protein and calories.
Emerging evidence suggests that signaling of myostatin,
IGF-I, and SOCS-2 is involved in the pathogenesis of muscle
wasting in uremia cachexia (Figure 7). Myostatin (also
known as growth/differentiation factor-8) is a member of the
transforming growth factor-b family, which plays an essential
role in the regulation of skeletal muscle mass. Myostatin is
expressed initially in the myotomal compartment of deve-
loping somites and continues to be expressed in muscle
throughout development and in adult animals. Mice with a
targeted disruption of the myostatin gene display a marked
increase in muscle mass, up to three times the normal size, as
a result of a combination of muscle fiber hyperplasia and
hypertrophy.11 IGF-I is essential for embryonic and postnatal
development of skeletal muscle and other tissues. Mice
engineered to lack IGF-I or the IGF-I receptor were
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Figure 6 | IGF-I and myostatin protein concentrations in
gastrocnemius muscle. Muscle protein was extracted and
assayed for IGF-I and myostatin concentrations using colorimetric
ELISA kits. Final results were analyzed and expressed as relative to
total muscle concentration. *Po0.03.
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significantly smaller than their control littermates and had
reduced muscle tissue, whereas transgenic mice with targeted
overexpression of IGF-I to muscle showed increased muscle
mass.12 We have proposed that the balance between the local
expression of myostatin and IGF-I represents a yin-and-yang
system regulating muscle mass in CKD.7 Sun et al.13 showed
that uremia and exercise have opposing effects in affecting
this balance of myostatin and IGF-I in the pathogenesis of
uremic wasting.
We demonstrated that myostatin mRNA was increased,
whereas IGF-I mRNA was decreased in skeletal muscle as well
as WAT in uremic mice. We further showed that myostatin
protein concentrations were significantly increased and IGF-I
protein concentrations were decreased in skeletal muscle in
uremic mice compared with sham controls. The results of
this study are in accordance with the literature. Ding et al.14
found decreased IGF-I mRNA and protein in rats with
chronic renal insufficiency compared with pair-fed, sham-
operated controls. Tonshoff et al.15 also found that rats with
chronic renal insufficiency displayed reduced hepatic, lung,
and muscle IGF-I mRNA. AgRP administration corrected
these uremic molecular perturbations. This was accompanied
by the improvement in weight gain as well as LBM as
measured by dual-energy X-ray (DEXA).
The myostatin and IGF-I gene expression changes were
similar in WAT in uremic mice in which there was a loss of FM
after induction of CKD. Following improvement in adipose
tissue mass induced by AgRP, there was correction of IGF-I but
no change in myostatin gene expression. This is not surprising, as
IGF-I signaling is involved in adipogenesis,16 whereas there is no
current information on the role of myostatin in adipose tissue.
A growing body of evidence suggests that SOCS proteins
regulate GH and IGF-I signaling pathways. Mice lacking
SOCS-2 exhibit accelerated postnatal growth resulting in
adult mice that are 1.3–1.5 times the size of normal mice.17
Schaefer et al.18 showed that CKD causes a post-receptor
defect in GH signaling transduction, which was accompanied
by increased mRNA levels of the intracellular feedback
regulatory proteins SOCS-2 and SOCS-3 in the liver of
uremic animals. The results from this study confirm and
extend these previous results in the literature. SOCS-2 gene
expression was increased significantly in the skeletal muscles
in our uremic animals fed ad libitum. Although intracranial
AgRP administration in pair-fed uremic animals suppressed
SOCS-2 expression, the latter still remained higher than the
values seen in sham-operated mice. Thus, no firm conclu-
sions can be made about the role of SOCS-2 in uremic
cachexia. SOCS-3 mRNA expression was not different among
the three experimental groups in our study. This latter result
was consistent with a study from Sun et al.,19 who showed
that muscle SOCS-3 mRNA levels were not changed in
uremic animals.
At the end of the experiment, all mice were fasted for 12 h
before killing and tissue collection, so the effects of short-
term fasting need to be considered. Recent studies suggested
that short-term fasting did not elicit significant changes in
the genes regulating either muscle-specific protein synthesis
or atrophy. Specifically, there were no significant changes in
either muscle or plasma IGF-I and myostatin gene expression
in human subjects, up to 40 h of fasting.20 Furthermore, after
an overnight fast, human muscle and abdominal fat SOCS-2
mRNA expression did not change compared with fed
controls.21
In summary, we showed that AgRP administration
ameliorated uremic cachexia independently of nutritional
effects and that the underlying peripheral molecular
mechanism involves the regulation of muscle mass via
myostatin and IGF-I balance.
MATERIALS AND METHODS
Animals
Male c57BL/6J mice from Jackson Laboratory, aged 8–10 weeks, were
used. Mice were raised in a 12-h light/12-h dark cycle. Individual
mice were housed and food intake was estimated by measuring the
weight of powdered food remaining in feeding chambers designed to
maximize spill capture. In this study, subtotal N mice were fed ad
libitum with powdered mouse diet 5015 containing 17% crude
protein (LabDiet, St Louis, MO, USA) that was weighed and
replaced daily. S mice were pair-fed with N mice. The physiological
fuel value of mouse diet 5015 is 3.83 kcal g1. Efficiency of food
consumption was calculated as the cumulative weight gain (in g)
divided by total food consumption (in g). All studies complied with
the Institutional Animal Care Committee and the NIH Guide for the
Care and Use of Laboratory Animals.
AgRP administration
Experiments were performed according to the protocol depicted in
Figure 8. The detailed procedure for intracerebroventricular (i.c.v.)
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Figure 7 | IGF-I, myostatin, and SOCS-2 abnormalities and
their aberrant signaling pathways leading to muscle wasting
in uremia cachexia. GH, growth hormone; GHR, GH receptor;
JAKs, Janus activated kinases; STATs, signal transducers and
activators; IGF-IR, IGF-I receptor; PI3K, phosphatidylinositol-3
kinase; GSK3b, glycogen synthase kinase 3b; mTOR, mammalian
target of rapamycin; FoxOs, forkhead family of the transcription
factors; MuRF-1, muscle ring finger-1.
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cannulation was described previously.9 The animal was housed
separately for 7 days for recovery before the subsequent operation.
The correct position of the cannula was confirmed by a positive
dipsogenic response to angiotensin II (Sigma-Aldrich, St Louis, MO,
USA). The correct cannula placement was also confirmed by
histological examination after studies were completed in which the
animal was infused with blue dye before killing and the brain was
examined for ventricular staining. Only those animals with correctly
positioned cannulae, independently assessed, were included in the
study. An individual mouse was handled daily for 3 consecutive days
before the initiation of the experiment, simulating the restraint used
during the injection of the compound. Normal saline or 2 nmol of
AgRP (82–131 amino-acid fragment; Phoenix Pharmaceuticals Inc.,
Burlingame, CA, USA) was infused over 45 s in lateral ventricle-
cannulated mice, using a 10-ml syringe (Hamilton Co., Reno, NV,
USA). N/AgRP mice were pair-fed with N mice. During 14 days of
study, experimental animals were infused with either normal saline
or AgRP at days 0, 3, 6, 9, and 12 relative to the initial injection.
Standard nephrectomy and sham operation
Uremia was induced in the animals by standard 5/6 subtotal
nephrectomy in a two-stage procedure as described.9 For each
successful nephrectomy, a subsequent sham control operation was
performed in a control animal.
Body composition
All animals underwent body composition analysis twice, that is, at the
start and at the end of the experiments by DEXA using a PIXImus
mouse densitometer (MEC Lunar Corp., Minster, OH, USA). The
instrument was calibrated at the start of each recording session with a
murine calibration standard. All animals were fasted for 12 h before
DEXA analysis to minimize the effect of ingested food.
Indirect calorimetry
All animals underwent indirect calorimetry analysis at the end of the
experiment. Oxygen consumption and carbon dioxide production
were simultaneously determined by indirect Oxymax calorimetry
(Columbus Instruments, Columbus, OH, USA). Mice were housed in
separated chambers at 24±1 1C. Animals were first acclimatized to the
chambers for 2 days. Measurements were recorded for 6–9 h during the
12-h light cycle. Samples were recorded every 3 min with the room air
reference taken every 30 min; the airflow to chambers was 500 ml min1.
Basal metabolic rate (ml kg1 h1) was calculated as the average of the
lowest three readings obtained during the recording period.
Blood chemistry analysis
After 14 days of observation, animals were killed and blood samples
were collected for subsequent serum chemistry analysis. Blood urea
nitrogen, serum creatinine, and blood bicarbonate levels were
assayed by standard laboratory methods.
Real-time semiquantitative PCR analysis
Total RNA from gastrocnemius muscles and WAT was extracted
and reversely transcribed with standard procedures. Appropriate
primers and probes for mouse IGF-I, myostatin, SOCS-2, SOCS-3,
and endogenous control GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) were obtained. Identities for mouse Taqman
Gene Expression Assays-On-Demand (ABI Applied Biosystems,
Foster City, CA, USA) for mouse IGF-I, myostatin, SOCS-2,
SOCS-3, and GAPDH were Mm00439560_m1, Mm00440328_m1,
Mm00850544_g1, Mm00545913_s1, and 4352339E. The PCR
amplification was performed in a final volume of 25 ml, containing
4 ml cDNA, 1.25 ml Taqman Gene Expression Assay for target gene,
and 1 Taqman Universal Master Mix. The parameters for ABI
Prism 7000 Sequence Detection System (Applied Biosystems) were
50 1C for 2 min, 95 1C for 10 min followed by 40 cycles of 95 1C for
15 s, and 60 1C for 1 min. Comparative 2DDCt method was used to
determine the relative quantification of the target gene. To
normalize each sample for RNA content, the control gene GAPDH
was used. Relative quantification of the target gene was related to the
PCR signal of the specific transcript of pair-fed S control mice. Final
results were expressed in arbitrary units, with 1 unit being the mean
mRNA level determined in the pair-fed S control mice.
IGF-I and myostatin protein expression
Colorimetric ELISA kits were used to quantitate muscle IGF-I (R&D
Systems, Minneapolis, MN, USA) and myostatin (Immundiagnostik
AG, Bensheim, Germany) protein concentrations. Muscle protein
was extracted with 0.1% Igepal CA630 non-ionic detergent (Sigma-
Aldrich) in phosphate-buffered saline with added Complete Mini
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN,
USA).22 Muscle total protein concentration was measured using DC
protein assay reagents (Bio-Rad, Hercules, CA, USA). Homogenates
from mouse muscle tissue were assayed for detectable levels of
mouse IGF-I and myostatin. Absorbance values were determined
with a GENios plate reader (Tecan Inc., Durham, NC, USA), and
concentrations of IGF-I or myostatin in samples were determined by
regression line curve fitting on log–log standard results. Final results
were expressed relative to total muscle concentration.
Statistical analysis
Data are expressed as mean±s.e.m. Results were analyzed by
Student’s t-test when two groups were included or by one-way
analysis of variance with post hoc analysis when three groups were
included. Data sets were analyzed for statistical significance using
SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA).
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Figure 8 | Schematic representation of the experimental
procedures. Surgical implantation of i.c.v. cannula was performed
in all mice approximately 3 weeks before the initiation of the
study. Subsequent two-stage 5/6 nephrectomy or sham operation
was performed. All animals underwent body composition analysis
twice, that is, at the start and at the end of a 2-week study by
DEXA. At the end of the experiment, the basal metabolic rates of
individual mouse were determined by indirect Oxymax
calorimetry analysis. At the end of the study, the animals were
killed after an overnight fast. Peripheral blood sample and various
tissue types were collected.
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